Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhulin Liu

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Clinical Medicine Insights. Oncology|November 17, 2022
First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent TreatmentsNaifu Nie, Jianghua Li, Jian Zhang, et al.
Communications Biology|February 24, 2022
Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signalingLi Li, Zhujun Li, Conghua Lu, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Clinical Medicine Insights. Oncology|November 17, 2022
First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent TreatmentsNaifu Nie, Jianghua Li, Jian Zhang, et al.
Communications Biology|February 24, 2022
Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signalingLi Li, Zhujun Li, Conghua Lu, et al.
Pageof 3